GRIT Biotechnology, a leading cell therapy specialist based in China, has entered into a strategic partnership with compatriot firm Quangang Pharmaceutical Co., Ltd. The collaboration aims to co-develop a combination therapy for solid tumors, leveraging tumor-infiltrating lymphocyte (TIL) therapy and recombination human interleukin-2 (IL-2).
Interleukin-2 (IL-2) products, which are already commercially available, have a wide range of applications in the treatment of various malignant tumors, including renal cell carcinoma, melanoma, breast cancer, bladder cancer, liver cancer, rectal cancer, lymphoma, and lung cancer. This partnership seeks to enhance the therapeutic potential of TIL therapy by combining it with the established benefits of IL-2 treatment.- Flcube.com
